Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis.
CONCLUSIONS: The overall costs of chemotherapy for patients diagnosed with castration resistant prostate cancer in Japan are high. Our findings can serve as a basis for health economic evaluations.
PMID: 29625534 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Healthcare Costs | Japan Health | Prostate Cancer | Research